Garcia-Manero, G <br/><br/>
Salvage therapy for refractory or relapsed acute lymphocytic leukemia.  [electronic resource] 

 -  Hematology/oncology clinics of North America  Feb 2001 
 - 163-205 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>0889-8588 
<br/><br/><label>Standard No.: </label>10.1016/s0889-8588(05)70204-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily B, Member 1--antagonists & inhibitors<br/>Adult<br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal--therapeutic use<br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis--drug effects<br/>Bone Marrow Transplantation<br/>Cancer Care Facilities--statistics & numerical data<br/>Child<br/>Chromosome Aberrations<br/>Clinical Trials as Topic<br/>Combined Modality Therapy<br/>DNA Methylation--drug effects<br/>Disease-Free Survival<br/>Drug Resistance, Neoplasm<br/>Enzyme Inhibitors--therapeutic use<br/>Humans<br/>Immunophenotyping<br/>Multicenter Studies as Topic<br/>Neoplasm Proteins--antagonists & inhibitors<br/>Oligonucleotides, Antisense--therapeutic use<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Recurrence<br/>Remission Induction<br/>Risk Factors<br/>Salvage Therapy<br/>Survival Analysis<br/>Texas--epidemiology<br/>Treatment Outcome